Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
KEYWORDS: people, treatment, anticoagulation, dvt, committee, anticoagulation treatment, evidence, vte, recommendations, risk, cancer, agreed, clinical, use, d-dimer

they might affect practice, see the rationale and impact section on investigations for cancer. Full details of the evidence and the committee's discussion are in evidence review C: investigations for cancer in people with unprovoked venous thromboembolism. 1.9 Thrombophilia testing 1.9.1 Do not offer testing for hereditary thrombophilia to people who are continuing anticoagulation treatment. [2012, amended 2020] 1.9.2 Do not offer thrombophilia testing to people who have had provoked DVT or PE. [2012] 1.9.3 Consider testing for antiphospholipid antibodies in people who have had unprovoked DVT or PE if it is planned to stop anticoagulation treatment, but be aware that these tests can be affected by anticoagulants and specialist advice may be needed. [2012, amended 2020] 1.9.4 Consider testing for hereditary thrombophilia in people who have had unprovoked DVT or PE and who have a first-degree relative who has had DVT or PE if it is planned to stop anticoagulation treatment, but be aware that these tests can be affected by anticoagulants and specialist advice may be needed. [2012, amended 2020] 1.9.5 Do not routinely offer thrombophilia testing to first-degree relatives of people with a history of DVT or PE and thrombophilia. [2012] Terms used in this guideline Active
